Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT07094789

Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression

Led by Sunnybrook Health Sciences Centre · Updated on 2025-08-11

20

Participants Needed

1

Research Sites

107 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the safety and initial effectiveness of Magnetic Resonance-guided focused ultrasound neuromodulation using the Next Generation Dome Helmet (NGDH) device in patients with treatment-resistant depression. This is a prospective, single-arm, non-randomized study. Participants will: * Undergo two focused ultrasound treatment sessions targeting nodes of the cortical-striatal-thalamic circuit (CSTC) , spaced four weeks apart. * Return for follow-up visits at 24 hours, 2 weeks, and 4 weeks after each treatment session, during which clinical scales and imaging assessments will be conducted to monitor safety and clinical effects.

CONDITIONS

Official Title

Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide informed consent
  • Between 18 and 65 years old
  • Diagnosed with major depressive disorder (MDD) according to DSM-5 criteria
  • Total score over 20 on the Hamilton Depression Rating Scale (HAMD-17)
  • On stable psychiatric medications for at least 30 days before enrollment
  • Documented previous trial of at least two first-line antidepressant agents at adequate dose and duration, confirmed by two psychiatrists
  • Documented previous trial of cognitive behavioral therapy (CBT) or psychotherapy for MDD lasting at least 6 weeks
Not Eligible

You will not qualify if you...

  • Pregnant or intending to become pregnant during the study period
  • Diagnosis of moderate or greater substance use disorder (excluding cannabis or nicotine) or if substance use is primary focus of treatment
  • Known active seizure disorder or significant head injury with imaging-verified lesion
  • Unstable medical illness
  • Not eligible for 3-Tesla MRI (e.g., MRI-incompatible pacemaker)
  • Unable to reliably attend required screening, treatment, or follow-up appointments
  • Severe claustrophobia preventing completion of MRI procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada, M4N 3M5

Actively Recruiting

Loading map...

Research Team

N

Nir Lipsman, MD, PhD, FRCSC

CONTACT

A

Anusha Baskaran, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression | DecenTrialz